A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies

This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.

Inclusion Criteria:

• Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL
• Measurable lymphadenopathy
• Requires therapy

Exclusion Criteria:

• Recent history of a major non-lymphoid malignancy
• Evidence of ongoing infection
• Concurrent participation in another therapeutic clinical trial